AstraZeneca Total Assets 2006-2018 | AZN

AstraZeneca total assets from 2006 to 2018. Total assets can be defined as the sum of all assets on a company's balance sheet.
  • AstraZeneca total assets for the quarter ending December 31, 2018 were $60.651B, a 4.27% decline year-over-year.
  • AstraZeneca total assets for 2018 were $60.651B, a 4.27% decline from 2017.
  • AstraZeneca total assets for 2017 were $63.354B, a 1.32% increase from 2016.
  • AstraZeneca total assets for 2016 were $62.526B, a 4.11% increase from 2015.
AstraZeneca Annual Total Assets
(Millions of US $)
2018 $60,651
2017 $63,354
2016 $62,526
2015 $60,056
2014 $58,595
2013 $55,899
2012 $53,534
2011 $52,830
2010 $56,127
2009 $54,920
2008 $46,784
2007 $47,957
2006 $29,932
2005 $24,840
AstraZeneca Quarterly Total Assets
(Millions of US $)
Q4 2018 $60,651
Q3 2018 $61,443
Q2 2018 $61,344
Q1 2018 $63,281
Q4 2017 $63,354
Q3 2017 $64,587
Q2 2017 $65,119
Q1 2017 $60,959
Q4 2016 $62,526
Q3 2016 $63,222
Q2 2016 $64,419
Q1 2016 $64,323
Q4 2015 $60,056
Q3 2015 $54,118
Q2 2015 $55,169
Q1 2015 $53,701
Q4 2014 $58,595
Q3 2014 $56,164
Q2 2014 $58,539
Q1 2014 $59,390
Q4 2013 $55,899
Q3 2013 $54,121
Q2 2013 $53,987
Q1 2013 $52,329
Q4 2012 $53,534
Q3 2012 $52,448
Q2 2012 $51,390
Q1 2012 $50,763
Q4 2011 $52,830
Q3 2011 $52,576
Q2 2011 $53,406
Q1 2011 $54,534
Q4 2010 $56,127
Q3 2010 $56,390
Q2 2010 $54,647
Q1 2010 $54,075
Q4 2009 $54,920
Q3 2009 $51,899
Q2 2009 $50,200
Q1 2009 $46,515
Q4 2008 $46,784
Q3 2008 $48,073
Q2 2008 $50,202
Q1 2008 $48,458
Q4 2007 $47,957
Q3 2007 $0
Q2 2007 $47,600
Q1 2007 $29,565
Q4 2006 $29,932
Q3 2006 $28,122
Q2 2006 $28,459
Q1 2006 $25,149
Q4 2005 $24,840
Q3 2005 $24,527
Q2 2005 $24,884
Q1 2005 $24,849
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $98.276B $22.090B
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $368.953B 16.73
Pfizer (PFE) United States $234.424B 13.13
Merck (MRK) United States $197.334B 16.86
Novartis AG (NVS) Switzerland $176.507B 15.01
Eli Lilly (LLY) United States $119.326B 20.72
Novo Nordisk (NVO) Denmark $118.242B 19.13
AbbVie (ABBV) United States $114.422B 9.81
Sanofi (SNY) France $103.609B 12.79
GlaxoSmithKline (GSK) United Kingdom $98.852B 12.98
Bristol-Myers Squibb (BMY) United States $74.378B 11.44